Biotech startup Zumutor Biologics raised $6.2 million in Series A4 led by Siana Capital


Biotech startup Zumutor Biologics raised $6.2 million in Series A4 led by Siana Capital along with existing investors Accel and Bharat Innovation Fund.


Zumutor is a pioneer in the field of targeted NK cell therapeutics in the immuno-oncology industry. The funding is expected to catapult the startup into the next stage of unlocking value globally. Zumutor stated that the completion of phase 1 trials will provide it with a plethora of options for strategic licencing of its lead asset, with the possibility of enlisting biopharma companies to conduct phase 2-4 trials once the molecule's safety is established. Typically, biotech R&D firms like Zumutor licence their molecules to biopharma majors, who then launch the products as either a monotherapy or a combination therapy once all phases of clinical trials are completed.

23 views0 comments